TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Sabre Insurance Group plc ( (GB:SBRE) ) is now available.
Sabre Insurance Group plc has announced that as of 31 October 2025, its issued and fully paid share capital consists of 246,600,000 ordinary shares, each with a nominal value of £0.001 and one voting right per share. This update is crucial for shareholders as it determines the denominator for calculating their interest in the company under the Disclosure and Transparency Rules, impacting how they report changes in their holdings.
The most recent analyst rating on (GB:SBRE) stock is a Buy with a £1.62 price target. To see the full list of analyst forecasts on Sabre Insurance Group plc stock, see the GB:SBRE Stock Forecast page.
Spark’s Take on GB:SBRE Stock
According to Spark, TipRanks’ AI Analyst, GB:SBRE is a Neutral.
Sabre Insurance Group’s overall stock score is bolstered by strong financial performance, particularly in revenue growth and profitability improvements, along with an undervalued stock price and attractive dividends. While the technical analysis suggests some caution due to the stock trading below key moving averages, the positive corporate events, such as insider buying and strategic initiatives, reinforce confidence in the company’s prospects. The absence of earnings call data limits a more comprehensive assessment.
To see Spark’s full report on GB:SBRE stock, click here.
More about Sabre Insurance Group plc
Sabre Insurance Group plc operates in the insurance industry, primarily offering motor insurance products. The company focuses on providing straightforward and reliable insurance services to its customers.
Average Trading Volume: 406,119
Technical Sentiment Signal: Buy
Current Market Cap: £329.3M
Learn more about SBRE stock on TipRanks’ Stock Analysis page.